LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
All content for i3 Health Podcast is the property of i3 Health and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 2
i3 Health Podcast
24 minutes 28 seconds
3 months ago
Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 2
i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC).
In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!
Click below to complete the claim your CE credit:
Module 2: bit.ly/405xEJO
Click below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing Recommendations
Module 1: bit.ly/49NCaQu
i3 Health Podcast
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
